Case Study: Managing Multiple Outcome Measures & Patient Recruitment For Phase IIB RRMS Clinical Trial
Before viewing the case study, you may also be interested in our webinar with GeNeuro.
The development of new medicines targeting multiple sclerosis (MS) can take 10 to 15 years from testing in a laboratory to becoming commercially available. For every 10,000 compounds tested, fewer than one or two become licensed treatments. Many are rejected on the grounds of their safety, quality, and efficacy.1
As a full-service CRO, we have an outstanding track record in starting up and executing MS studies, including beta-interferons, glatiramer acetate monoclonal antibodies, and oral preparations for disease-modifying approaches.
In this case study, learn how Worldwide Clinical Trials helped GeNeuro address their key study challenges.